Physio-control contacted the customer to request additional information on the patient.
No response has been received from the customer.
Patient fields in which information is not provided were intentionally left blank.
Physio-control performed and initial evaluation of the customers device and was unable to duplicate the reported issue.
Physio performed a clinical review of the device data and determined device use caused the reported death stating, the patient was in a viable state with organized ecg rhythm or other evidence of viability (e.
G.
, vital signs, level of consciousness), and the malfunction/use error placed the patient in a life-threatening condition.
The code-stat file retrieved from the device contained a 1 hour, 52 minute, and 20 second case.
The patient presented in atrial fibrillation with a variable heart rate ranging from 60 beats per minute to 70 beats per minute from the time of leads on at 10:27:28 am to 11:31:31 am.
At 11:31:31 am the patient was defibrillated at 200 joules (j) converting them into ventricular fibrillation (vf).
The patient remained in vf throughout the remainder of the case, receiving an additional 15 200 j shocks.
The clinical review also noted one use error stating, the user defibrillated an organized rhythm converting the patient into vf.
Per the lp20e operating instructions, page ix: indications defibrillation is a recognized means of terminating certain potentially fatal arrhythmias, such as ventricular fibrillation and symptomatic ventricular tachycardia.
Delivery of this energy in the synchronized mode is a method for treating atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia and, in relatively stable patients, ventricular tachycardia.
Note: the lifepak 20e defibrillator/monitor comes configured with an escalating energy protocol (200 j, 300 j, 360 j).
Energy escalation up to 360 j is recommended for difficult to defibrillate patients.
Physio-control continues to investigate the reported failure and will submit a supplemental report on this event to the fda as provided by 21 cfr 803.
56.
|